HGH Fragment 176-191

HGH Fragment 176‑191 is a 16‑amino‑acid piece taken from the C‑terminal end of human growth hormone. It is also known in the literature as AOD9604 or a modified C‑terminal GH fragment. The peptide was developed to capture the fat‑mobilizing (lipolytic) effects of growth hormone while avoiding the broad receptor activation that can lead to fluid retention, joint pain, and elevated IGF‑1.

Unlike full growth hormone or GH secretagogues such as ipamorelin, HGH Fragment 176‑191 does not appear to stimulate the GH‑IGF‑1 axis The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration. Instead, early animal work showed that chronic treatment increased fat oxidation and weight loss in obese mice, sparking interest in its potential for body‑composition research Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment. Human safety data exist from a tolerability study, but strong clinical efficacy for weight loss has not been established Safety and Tolerability of the Hexadecapeptide AOD9604 in Humans.

The current evidence base is limited; the compound is not approved as a medication for obesity or any other indication. In practice, it is used in research and community settings for fat‑loss purposes, often in cutting protocols, although the translation from animal studies to human outcomes remains uncertain The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration.

HGH Fragment 176‑191 is believed to work through a pathway that is separate from the classic growth hormone receptor. In obese mice, chronic administration of a modified C‑terminal GH fragment increased fat oxidation and reduced body weight, supporting a direct effect on lipid metabolism Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment.

The key distinction is that available review data indicate AOD9604 acts independently of the GH receptor and does not produce systematic somatotropic activation (i.e., it does not raise GH or IGF‑1 levels the way GH itself or secretagogues do) The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration. This means it is not expected to cause the same water retention, soft‑tissue growth, or joint discomfort seen with full GH.

Instead, the fragment appears to shift substrate utilization toward fat oxidation over carbohydrate burning. This selective lipolytic signaling is the main rationale for its investigation in body‑composition research. However, the detailed molecular cascade remains largely extrapolated from animal data, and human studies confirming these effects are not yet available The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration+1.

Animal Data

In obese mice, daily treatment with a modified GH C‑terminal fragment led to significantly increased fat oxidation and greater weight loss compared to untreated controls Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment. This is the strongest direct efficacy signal in the current literature.

Human Evidence

Human data are limited to a safety and tolerability study of AOD9604, which reported that the compound was generally well tolerated but did not provide robust weight‑loss efficacy results Safety and Tolerability of the Hexadecapeptide AOD9604 in Humans. A phase 2B obesity program was later terminated after the results did not support commercial viability The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration.

Practitioner Observations

In community settings, users often report gradual reductions in waist circumference and an improved ability to maintain a calorie deficit when following protocols of 250–500 mcg per day for 8–12 weeks. These observations remain anecdotal and should be interpreted cautiously, as the evidence for clinically meaningful fat loss in humans is not yet established The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration+1.

Because no standardized human dosing regimen has been validated in controlled trials, research protocols are based on community practice and the limited available evidence. The most common approach uses subcutaneous injection once or twice daily, with doses typically ranging from 250 to 500 mcg per day The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration+1.

Starting protocol: A conservative entry point is 250 mcg once daily for the first 1–2 weeks to assess tolerability. If no significant side effects occur, the dose may be increased to 250–500 mcg per day, often split into morning and (optionally) afternoon doses Safety and Tolerability of the Hexadecapeptide AOD9604 in Humans.

Timing: Many protocols administer the peptide in a fasted state, particularly before morning cardio, to capitalize on the body’s natural fat‑oxidation window. Some protocols add a second dose later in the day, separated by at least 4–6 hours from meals to keep insulin low.

Duration: Cycles typically last 6–12 weeks, with a break of 2–4 weeks afterward to evaluate whether body‑composition changes are maintained. The interactive calculator below can help convert these doses into convenient injection volumes once the peptide has been reconstituted.

HGH Fragment 176‑191 is supplied as a lyophilized (freeze‑dried) powder that must be mixed with a sterile diluent before injection. Bacteriostatic water is the most common choice for multi‑dose vials, as the benzyl alcohol preservative helps maintain sterility over several weeks of use. Sterile water can be used if the entire vial will be consumed within a few days.

Aseptic technique is essential: always swab the vial tops and injection site with alcohol, use a fresh sterile needle, and avoid touching any surfaces that will contact the solution. Add diluent slowly down the side of the vial and swirl gently—never shake—to dissolve the powder.

After reconstitution, store the vial in the refrigerator at 2–8°C (36–46°F). Protect from light and avoid repeated freezing. A solution mixed with bacteriostatic water is generally used within 28–30 days; with sterile water, it is best used within 72 hours The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration. Do not use if the solution becomes cloudy or contains particles.

For specific concentration and dosing calculations, use the interactive tool on this page.

Direct drug interaction studies for HGH Fragment 176‑191 are lacking. However, the available mechanistic and animal data allow a cautious assessment of likely interactions.

Glucose‑lowering medications (insulin, sulfonylureas, metformin, GLP‑1 agonists): Because the fragment shifts metabolism toward fat oxidation, it could theoretically alter glucose requirements, especially during calorie restriction. Monitor fasting glucose more frequently if used alongside any antihyperglycemic agent The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration+1.

GH secretagogues and GH itself: While HGH Fragment 176‑191 does not activate the GH receptor, it is often stacked with compounds that do (e.g., ipamorelin, CJC‑1295, tesamorelin). The endocrine risks of the companion peptide—elevated IGF‑1, edema, insulin resistance—should not be ignored. Combined protocols require monitoring of IGF‑1 and glucose The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration.

Anticancer agents: A single in‑vitro study found that the fragment enhanced the toxicity of doxorubicin against breast cancer cells, but this has no established clinical relevance. Avoid unsupervised use during chemotherapy .

Stimulants and thermogenic supplements: When combined with caffeine, yohimbine, or other fat‑burning stacks, there is a theoretical risk of excessive energy deficit or sympathetic overstimulation. Monitor heart rate and sleep quality if such combinations are used Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment.

Structured cycling is used in practice to evaluate whether the compound produces a meaningful change in body composition during a defined period, not because of known receptor desensitization. Since HGH Fragment 176‑191 does not stimulate the GH‑IGF‑1 axis, there is no theoretical need for endocrine “washout” The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration.

Typical cycle lengths:

• A first‑time assessment often runs 4–6 weeks at 250 mcg once daily.
• A standard research block lasts 8–12 weeks at 250–500 mcg per day.
• After a cycle, a 2–4‑week break allows the researcher to observe whether any changes persist.

When to pause or stop: If no measurable improvement in waist circumference or fat‑loss trend is seen after 4–6 weeks of consistent dosing and a controlled diet, the compound may not be effective in that case Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment+1. Persistent injection‑site irritation, headaches, or unexplained fatigue are also reasons to discontinue. Given the prevalence of mislabeled products in the peptide market, any unusual symptom should raise suspicion about the material’s identity The use and abuse of growth hormone in sports.

In research and community settings, HGH Fragment 176‑191 is frequently combined with other compounds to target fat loss from multiple angles.

With GH secretagogues (ipamorelin, CJC‑1295, GHRP‑2): The fragment is thought to add a lipolytic component without further GH‑axis activation, while the secretagogue drives pulsatile GH release. However, the safety profile of the combination is undefined, and monitoring should focus on the GH‑related agent’s effects The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration.

With GLP‑1 agonists (semaglutide, tirzepatide): This stack aims to pair appetite suppression and improved insulin sensitivity (from the GLP‑1 agent) with direct fat‑oxidation signaling (from the fragment). No human data exist to support this combination, but mechanistic rationale exists. Closer glucose monitoring is advised, especially in a calorie deficit Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment.

With recovery peptides (BPC‑157, TB‑500): Anecdotal reports suggest that adding HGH Fragment 176‑191 during a cut may help preserve muscle while the recovery peptides support tissue repair. No direct interaction data are available; this stack is community‑based.

Stacking any unapproved peptides multiplies the uncertainty and should be approached with extra caution regarding product purity and unanticipated effects The use and abuse of growth hormone in sports.

HGH Fragment 176‑191 (AOD9604) is not approved by the FDA or any other major regulatory agency for therapeutic use. An obesity‑development program was discontinued after phase 2B trials did not demonstrate sufficient clinical benefit The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration+1.

Legally, it exists in a gray area: it is not a controlled substance, but it is not a prescription medicine either. It is often sold as a research chemical for laboratory use, and any human application is off‑label and unsupported by regulatory frameworks.

Anti‑doping status: The World Anti‑Doping Agency (WADA) prohibits growth hormone fragments under the S2 category of peptide hormones and growth factors. HGH Fragment 176‑191 is banned at all times, both in‑ and out‑of‑competition, for athletes under WADA‑code testing The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration+1. Annual banned‑substance reviews continue to refine methods for detecting such peptide‑analog drugs Exergy, economic, and environmental study for flat plate solar collector using pulsating flow.

What the Evidence Shows

A human tolerability study found that AOD9604 was generally well tolerated, with no signal of systematic GH‑axis activation Safety and Tolerability of the Hexadecapeptide AOD9604 in Humans. This suggests a lower risk of typical GH‑related side effects such as edema, carpal tunnel syndrome, or joint pain The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration.

Common Reported Side Effects

In community use, the most frequent complaints are injection‑site irritation, transient headache, and mild nausea. These tend to be temporary and resolve within days of starting.

Uncommon but Noted Concerns

• Glucose effects: Older animal work with C‑terminal GH fragments showed hyperglycemic and insulin‑resistance effects, though less potent than full‑length GH The use and abuse of growth hormone in sports+1. Anyone with prediabetes, diabetes, or insulin resistance should monitor fasting glucose.
• Product quality: Falsified peptides are common in the unregulated market; impurities or mislabeled products can cause unexpected reactions The use and abuse of growth hormone in sports.

Contraindications

• Absolute: Hypersensitivity to the peptide, use of unverified/impure products.
• Relative: Diabetes, concurrent use of other GH‑axis drugs, history of cancer (theoretical IGF‑1 concerns when stacked with GH secretagogues), pregnancy/breastfeeding, and severe liver/kidney disease.

Monitoring Parameters

A prudent monitoring protocol includes fasting glucose and a comprehensive metabolic panel at baseline and end of cycle. If combined with GH secretagogues, also check IGF‑1. Persistent hyperglycemia, unexplained edema, or no body‑composition change after 6–8 weeks are reasons to discontinue The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration+1.